

ASX Announcement

Notice under section 708A(5)(e) of the Corporations Act

SYDNEY, 25 November 2013: Cellmid Limited (ASX: CDY) notifies, in accordance with section 708A(5)(e) of the Corporations Act, the details required under section 708A(6) in relation to the issue of securities in consideration for the acquisition by Cellmid of a minority shareholding in Advangen International Pty Ltd.

Details of the securities issued:

Class of securities:	Fully paid ordinary shares
ASX Code of the securities:	CDY
Date of issue of the securities:	25 November 2013
Total number of securities issued:	3,515,625

Cellmid also notifies, in accordance with section 708A(5)(e) of the Corporations Act, the details required under section 708A(6) in relation to the issue of securities under Cellmid's Employee Incentive Plan.

Details of the securities issued:

Class of securities:	Fully paid ordinary shares
ASX Code of the securities:	CDY
Date of issue of the securities:	25 November 2013
Total number of securities issued:	12,000,000

An Appendix 3B for the above securities was given to the ASX today.

Cellmid advises that:

- (a) the above securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, Cellmid has complied with the provisions of Chapter 2M, and section 674, of the Corporations Act as they apply to Cellmid; and
- (c) as at the date of this notice, there is no information that is excluded information within the meaning of sections 708A(7) and 708A(8) of the Corporations Act, being information that:
 - (1) has been excluded from a continuous disclosure notice in accordance with the Listing Rules of ASX; and
 - (2) investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - (A) the assets and liabilities, financial position and performance, profits and losses and prospects of Cellmid; or
 - (B) the rights and liabilities attaching to the shares or generally to the ordinary shares in the capital of Cellmid.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see www.cellmid.com.au.